The aim of the given study was to formation as well as development of patches of piroxicam. Piroxicam basically a steroidal anti-inflammatory drug. Less dosage result in the longer duration of action which make these patches a remarkable in curing the infection for the increase of transdermal properties of the patches various batches were prepared using hydroxyl propyl methyl cellulose, ethyl cellulose and poly vinyl pyrrolidone for best result various parameters are considered like thickness,weight are considered during various test in different batches and the last are i.e. the 6 th batch comes good result batch 6 th show best evaluation parameter whereas batch 7 th show a 95 % release of drug there parameters including moisture content and above mention were tested and were evaluated for best possible result.
INTRODUCTION
ransdermal drug delivery system is self-contained, discrete dosage form 1 in which drug stick to the body surface and delivers the drug, across the skin at controlled rate in to the blood stream. TDDS has been a great field of interest in recent times. Many drugs which can be injected directly into the blood stream via skin have been formulated by TDDS 2 . Transdermal drug delivery system (TDDS) provides a means to sustain drug release as well as reduce the intensity of action and thus reduce the side effects associated with its oral therapy 3 .
Advantages
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 Transdermal medication delivers a steady infusion of a drug over an extended period of time.
 An equivalent therapeutic effect can be elicited via transdermal drug input with a lower daily dose of the drug than is necessary, e.g. the drug is given orally.
Disadvantages
4-8-9
 Many drugs especially drugs with hydrophilic structures permeate the skin too slowly to be of therapeutic benefit.  The barrier function of the skin changes from one site to another on the same person, from person to person and also with age.
Drug delivery routes across human skin
Drug molecules can penetrate by three pathways: 
Factors affecting transdermal drug delivery:-(A) Physicochemical properties of permeant
Partition coefficient 3 For molecules with intermediate partition coefficient (log K 1 to 3) and for highly lipophilic molecules (log K>3), the intercellular route will be almost the pathway used to traverse the stratum corneum. However, for these molecules a further consideration is the ability to partition out of the stratum corneum into the aqueous viable epidermal tissues. For more hydrophilic molecules (log K<1), the transcellular route probably predominates. 3 A second major factor in determining the flux of a material through human skin is the size of the molecule. However, for simplicity the molecular weight is generally taken as an approximation of molecular size. It has been suggested that an inverse relationship existed between transdermal flux and molecular weight of the molecule. 3 It is well known that most organic materials with high melting points have relatively low aqueous solubility at normal temperature and pressure. The lipophilic molecules tend topermeate through the skin faster than more hydrophilic molecules. However, while lipophilicity is a desired property of transdermal candidates, it is also necessary for the molecule to exhibit some aqueous solubility since topical medicaments are generally applied from an aqueous formulation.
Molecular size
Solubility/melting point
B) Physicochemical properties of the drug delivery system
Release characteristics 7 Solubility of the drug in the vehicle determines the release rate. The mechanism of drug release depends on the following factors:
 Whether the drug molecules are dissolved or suspended in the delivery systems.  The interfacial partition coefficient of the drug from the delivery system to the skin tissue.  pH of the vehicle.
C) Physiological factors
Skin barrier properties in the neonate and young infant
The skin of newborns is known to be relatively susceptible to irritants, other variables related to stratum corneum function such as pH and stratum corneum hydration may enhance the irritant potential to newborn skin.
Skin barrier properties in aged skin
There are changes in the physiology of aged skin (>65 years). The corneocytes are shown to increase in surface area which may have implications for stratum corneum function due to the resulting decreased volume of intercorneocyte space per unit volume of stratum corneum.
Race
3
Racial differences between black and white skins have been shown in some anatomical and physiological functions of the skin although data is relatively sparse. In black skin, increased intracellular cohesion, higher lipid content and higher electrical skin resistance levels compared to whites have been demonstrated. 3 The human body maintains a temperature gradient across the skin from around 37 ºC to around 32 ºC at the outer surface.
Skin temperature
COMPONENTS OF TRANSDERMAL PATHCHES:-(I) Polymer Matrix1
The polymer controls the release of the drug from the device. The following criteria should be satisfied for a polymer to be used in transdermal patches.
(a) Molecular weight, chemical functionality of the polymer should be such that the specific drug diffuses properly and gets released through it.
 The polymer should be stable.  The polymer should be nontoxic 
Physiochemical properties
1) The drug should have a molecular weight less than 1000 Daltons. 2) The drug should have affinity for both lipophilic and hydrophilic phases.
Biological properties
a. The drug should be potent with a daily dose of the order of a few mg/day. b. The half life (t½) of the drug should be short. c. The drug must not produce allergic response.
(III) Permeation Enhancer
The flux J. of drug across the skin can be write As 
TYPES OF TRANSDERMAL PATCHES
10
Single-layer Drug-in-Adhesive
The adhesive layer of this system also contains the drug. In this type of patch the adhesive layer not only serves to adhere the various layers together, along with the entire system to the skin, but is also responsible for the releasing of the drug.
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Reservoir
Unlike the Single-layer and Multi-layer Drug-in adhesive systems the reservoir transdermal system has a separate drug layer. 
METHODS OF PREPARATION OF TRANSDERMAL PATCHES
Asymmetric TPX membrane method 11 A prototype patch can be fabricated for this a heat sealable polyester film (type 1009, 3m) with a concave of 1cm diameter will be used as the backing membrane. Drug sample is dispensed into the concave membrane, covered by a TPX {poly (4-methyl-1-pentene)} asymmetric membrane, and sealed by an adhesive.
Circular teflonmould method
12
Solutions containing polymers in various ratios are used in an organic solvent. Calculated amount of drug is dissolved in half the quantity of same organic solvent. Enhancers in different concentrations are dissolved in the other half of the organic solvent and then added. Di-Nbutylphthalate is added as a plasticizer into drug polymer solution. The total contents are to be stirred for 12 hrs and then poured into a circular teflonmould. The moulds are to be placed on a leveled surface Associate in Nursingd lined with inverted funnel to regulate solvent vaporization in a very streamline flow hood model with an air speed of zero.5 m/s. The solvent is allowed to evaporate for twenty-four hrs. The dried films ar to be keep for one more twenty four hrs at 25±0.5°C in a very desiccators containing colloid before analysis to eliminate aging effects. The kind films ar to be evaluated at intervals one week of their preparation.
Mercury substrate method
13
In this method drug is dissolved in polymer solution along with plasticizer. The higher than resolution is to be stirred for 10-quarter-hour to provide an even dispersion and poured in to a leveled mercury surface, lined with inverted funnel to manage solvent evaporation.
By using "IPM membranes" method 14 In this methodology drug is distributed in a very mixture of water and propanediol containing carbomer 940 compound and stirred for twelve hrs in magnetic stirrer. The dispersion is to be neutral and created viscous by the addition of triethanolamine. Buffer pH scale seven.4 will be employed in order to get resolution gel, if the drug solubility in solution is extremely poor. The shaped gel are going to be incorporated within the IPM membrane.
By using "EVAC membranes" method 15 In order to prepare the target transdermal therapeutic system, 1% carbopol reservoir gel, polyethelene (PE), ethylene vinyl acetate copolymer (EVAC) membranes can be used as rate control membranes. If the drug is not soluble in water, propylene glycol is used for the preparation of gel. Drug is dissolved in propylene glycol, carbopol resin will be added to the above solution and neutralized by using 5% w/w sodium hydroxide solution. The drug (in gel form) is placed on a sheet of backing layer covering the specified area. A rate controlling membrane will be placed over the gel and the edges will be sealed by heat to obtain a leak proof device. 16 Transdermal drug delivery system may produce unstable matrices if the loading dose is greater than 10 mg. Aluminium backed adhesive film method is a suitable one. For preparation of same, chloroform is choice of solvent, because most of the drugs as well as adhesive are soluble in chloroform. The drug is dissolved in chloroform and material is going to be additional to the drug answer and dissolved. A custammade aluminum former is lined with foil and also the ends blanked off with tight cork blocks.
Aluminium backed adhesive film method
Preparation of TDDS by using Proliposomes
17-18
The proliposomes area unit ready by carrier technique exploitation film deposition technique. From the soonerreference drug and emulsifier within the quantitative relation of zero.1:2.0 are often used as AN optimized one. The proliposomes area unit ready by taking 5mg of water pill powder during a one hundred cubic centimeter sphericalbottom flask that is unbroken at 60-70°c temperature and also the flask is revolved at 80-90 revolutions per minute and dried the water pill at vacuum for half-hour. Once drying, the temperature of the water bat is adjusted to 20-30°C. Drug and lecithin are dissolved during a appropriate organic solvent mixture, a 0.5ml aliquot of the organic answer is introduced into the spherical flat-bottom flask at 37°C, once complete drying second aliquots (0.5ml) of the answer is to be supplementary. Once the last loading, the flask containing proliposomes area unit connected during a lyophilizer and afterwards drug loaded water pill powders (proliposomes) area unit placed during a desiccator over night then sieved through one hundred mesh. The collected powder is transferred into a glass bottle and keep at the freeze temperature till characterization.
By using free film method 19 Free film of cellulose acetate is prepared by casting on mercury surface. A polymer solution 2% w/w is to be prepared by using chloroform. Plasticizers are to be
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[122] CODEN (USA): AJPRHS incorporated at a concentration of 40% w/w of polymer weight. Five ml of polymer solution was poured in a glass ring which is placed over the mercury surface in a glass petri dish. The rate of evaporation of the solvent is controlled by placing an inverted funnel over the petri dish. The film formation is noted by observing the mercury surface after complete evaporation of the solvent. The dry film will be separated out and stored between the sheets of wax paper in a desiccator until use. Free films of different thickness can be prepared by changing the volume of the polymer solution.
CHARACTERIZATION OF TRANSDERMAL PATCHES
Thickness of the patch [19] [20] The thickness of the drug loaded patch is measured in different points by using a digital micrometer and the average thickness and standard deviation is determined to ensure the thickness of the prepared patch.
Weight uniformity
The prepared patches are dried at 60°c for 4hrs before testing. A specified area of patch is to be cut in different parts of the patch and weigh in digital balance. The average weight and standard deviation values are to be calculated from the individual weights 21
Percentage Moisture content
The prepared films are to be weighed individually and to be kept in a desiccators containing fused calcium chloride at room temperature for 24 hrs. After 24 hrs the films are to be reweighed and determine the percentage moisture content from the below mentioned formula [21, 23] .
% Moisture content = Initial weight -Final weight X 100 Final weight
Content uniformity test
10 patches are selected and content is determined for individual patches. If 9 out of 10 patches have content between 85% to 115% of the specified value and one has content not less than 75% to 125% of the specified value, then transdermal patches pass the test of content uniformity. But if 3 patches have content in the range of 75% to 125%, then additional 20 patches are tested for drug content. If these 20 patches have range from 85% to 115%, then the transdermal patches pass the test. 
MATERIAL AND METHODS:
Preformulation studies
Preformulation testing is the first step in the rational development of dosage forms of a drug. It can be defined as an investigation of physical and chemical properties of drug substance, alone and when in combined with excipients. The overall objective of the preformulation testing is to generate information useful to the formulator in developing stable and bioavailability dosage forms which can be mass produced.
The goals of preformulation studies are:
 To establish the necessary physicochemical characteristics of a new drug substance.  To determine its kinetic release rate profile.  To establish it's compatibility with different excipients.
Characterization of Piroxicam
Melting point determination
The melting point of piroxicam was determined by using melting point apparatus with the help of fine capillary.
Spectroscopic studies FTIR spectrum interpretation
The infrared spectrum of the pure piroxicam sample was recorded and the spectral analysis was done. The dry sample of drug was directly placed after mixing and triturating with dry potassium bromide.
UV Analysis
A standard solution (10µg/ml) of Piroxicam was prepared in 0.1M NaOH and scanned by UV-VIS spectrophotometer (Lab India) between 200 to 400nm. The λ max was found to be 336 nm.
Construction of calibration curve of piroxicam
Accurately weighed 10 mg of drug was dissolved in 100 ml of 0.1M NaOH to give a solution of 100 µg/ml concentration. From this solution 1ml was taken and diluted to 10 ml using 0.1M NaOH to get a stock solution of 10µg/ml. From this stock solution various aliquots ranging from 1-10 µg/ml were prepared. The absorbance of these solutions was measured spectrophotometrically at 336 nm against reference blank.
Determination of solubility of Pirocxicam
Piroxicam solubility was determined in distilled water and phosphate buffer. The procedure can be detailed as follows:-in small glass vials solvent was taken and solubility was determined by making saturated solution of drug the drug was gradually added till the solutions turned cloudy indicating the presence of undissolved drug the solutions were kept at rest for 24hrs to assist the attainment of equilibrium with undissolved drug particles the supernatants were decanted and filtered through filter paper the filtrates were suitably diluted and the absorbance were measured at 336 nm.
Partition coefficient
The partition coefficient of the drug was determined by shaking equal volumes of oil and aqueous phases in a separating funnel drug solution of 1 mg/ml was prepared in octanol, 50 ml of this solution was taken in a separating funnel and shaken with an equal volume of distilled water for 10 minutes and allowed to stand for 1hour.Then the oil
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Formulation of Transdermal Patches
Transdermal patches of piroxicam were prepared by solvent casting technique. Ethanolic solution of polymer and drug along with polyethylene glycol (plasticizer) was prepared. The homogenous mixture was poured into plastic mould. The solvent was allowed to evaporate at controlled rate by placing an inverted funnel over the plastic mould. The control of evaporation is necessary for uniform drying of films. The drying was carried out at room temperature for duration of 24 hours. After 24 hours the dry films was removed from plastic mould and stored in desiccators until used. 
Evaluation of Transdermal Patches
Physical appearance
The prepared patches were physically examined for colour, clarity and surface texture.
Thickness of the patch
The thickness of the drug loaded patch was measured in different points by using a digital micrometer and determines the average thickness and standard deviation for the same to ensure the thickness of the prepared patch.
Weight uniformity
The prepared patches were dried at 60°c for 4hrs before testing. A specified area of patch was cut in different parts of the patch and weigh in digital balance. The average weight and standard deviation values are to be calculated from the individual weight.
Folding endurance
A strip of specific area was cut evenly and repeatedly folded at the same place till it broke. The number of times the film could be folded at the same place without breaking gave the value of the folding endurance .
Percentage Moisture content
The prepared films were weighed individually and to be kept in a desiccators containing fused calcium chloride at room temperature for 24 hrs. After 24hrs the films are to be reweighed and determine the percentage moisture content from the below mentioned formula.
Moisture content % = Initial weight − Final weight Final weight × 100
Percentage Moisture uptake
The weighed films were kept in desiccators at room temperature for 24hrs containing saturated solution of potassium chloride in order to maintain 84% RH. After 24hrs the films are to be reweighed and determine the percentage moisture uptake from the below mentioned formula.
Water vapor permeability
Glass vials of 5 ml capacity were washed thoroughly and dried to a constant weight in an oven. About 1gm of fused Calcium chloride was taken in the vials & the polymer films were fixed over the brim with the help of an adhesive tape. Then the vials were weighed and stored in a humidity chamber at 85 % RH condition for a period of 24 hours. The vials were removed and weighed at various time intervals like 3, 6, 12, 18 and 24 hrs to note down the weight gain.
Drug content
A specified area of patch was dissolved in a suitable solvent in specific volume. Then the solution is to be filtered through a filter medium and analyze the drug contain with the suitable method (UV or HPLC technique).
Percentage Elongation break test
The percentage elongation break was determined by noting the length just before the break point, the percentage elongation can be determined from the below mentioned formula. The FTIR spectra of piroxicam is shown in fig. 5.1 ., the main characteristic peak of piroxicam was the secondary amine N-H stretching which appeared at 3338 cm -1 . It has been reported that piroxicam has two inter convertible crystalline forms, namely the needle and cubic forms. The IR absorption peaks at 1634 cm -1 and 1629 cm -1 are assigned to the stretching of the amide carbonyl groups of the needle form and the cubic form respectively, the peak at 1529 cm -1 is due to the stretching of the second amide band for both crystalline forms of piroxicam. In the present study, the peak at 1629.55 cm -1 was found in the IR spectrum of piroxicam, suggesting that the cubic form of piroxicam was used. fig. 5.2 .showed an ester C=O stretching peak around 1724 cm -1 . The pattern of the selected transdermal formula showed band at 3336.88 cm -1, which was related to the N-H stretching and all the original peaks of the pure drug remained without changing, the existence of 1629 cm -1 indicates that the piroxicam was fixed in the cubic polymorphic form and no interaction with accidents occurred. Specific changes in IR spectra are not very clear. This could be due to variations in the resonance structure, rotation of a part of a molecule or certain bond, so it was can concluded that there is no interaction between piroxicam: HPMC:PVP:EC after evaporation of the solvent. 
Determination of λ max
A standard solution (10µg/ml) of Piroxicam was prepared in 0.1M NaOH and scanned by UV-VIS spectrophotometer (Lab India) between 200 to 400nm. The λ max was found to be 336 nmthe spectrum. 
Calibration curve of Piroxicam
Accurately weighed 10 mg of drug was dissolved in 100 ml of 0.1M NaOH to give a solution of 100 µg/ml concentration. From this solution 1ml was taken and diluted to 10 ml using 0.1M NaOH to get a stock solution of 10µg/ml. From this stock solution various aliquots ranging from 1-10 µg/ml were prepared. The absorbance of these solutions was measured spectrophotometrically at 336 nm against reference blank. Piroxicam was found to obey Beer-Lambert's law in the concentration range of 0-
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Solubility studies
The solubility of different formulation in water and pH 7.4 phosphate buffer was determined. Excess quantities of prepared formulation were taken into screw-capped 50 ml glass vials filled with water and pH 7.4 phosphate buffer. The vials were shaken for 24 hours on mechanical shaker. The solution was filtered through Whatmann filter paper and the drug concentration was determined spectrophotometrically. 
Moisture absorption
The % moisture absorption was in the range of 2.46 ± 0.29 to 4.73 ± 0.22 and4.14 ± 0.68 to 5.59 ± 0.17 at 75 % RH and 85 % RH, respectively.
Moisture content
The moisture content of the formulation ranges from 2.13 ± 0.39to 3.42 ±0.21.The value for the moisture content.
Folding Endurance
The folding endurance was found to be in the range of >100. This data revealed that the patches had good mechanical strength along with flexibility the values for all the formulation is tabulated.
Weight variation
The weight variation was to be in the range of 160.33 ± 0.47 to161.33 ± 0.95. The values for all the formulations are tabulated.
Drug content
The drug content was in the range of 94.57 ± 0.36 to97.58 ± 0.85. In-Vitro Studies Table 8 : The In vitro studies data of formulation of piroxicam. 
Drug Release Kinetic
The in vitro dissolution data of various formulation was analyzed by fitting the obtained data into various kinetic model to explain the release kinetics. In the present study, it was observed that the in vitro dissolution profile of piroxicam from all the formulations followed zero order kinetics. The n value from drug release experiment for the formulations containing ethyl cellulose polymer alone had n value from 0.383 to 0.427, indicated anomalous nonFickian type diffusion without swelling. In case of formulations containing HPMC alone or in combination with ethyl cellulose had values from 0.519 to 0.817, indicating anomalous non-Fickian type diffusion with swelling. 
CONCLUSION
In conclusion we have developed formulation and development of transdermal patches of piroxicam. Transdermal patches increase the patient compliance over conventional dosage form. Transdermal medication delivers a steady infusion of a drug over an extended period of time. An equivalent therapeutic effect can be elicited via transdermal drug input with a lower daily dose of the drug than is necessary, e.g. the drug is given orally.The preformulation study were investigated and had similarity with official standard (I. P. 1996) . The wavelength range determined using U.V. Spectrophotometer was found to be 336nm. HPMC, EC, PVP, Ethanol and PEG-400 were used in the formulation of transdermal patches.Eight batches of transdermal patches were prepared using different concentration HPMC, EC and PVP. Evaluation of each formulation was performed and formulation F6 was optimized best, because it had similarity with standard properties of transdermal patches. In-vitro release study provides information that transdermal patch is able to release 99.9% of drug.
